ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
ALT5 Sigma (NASDAQ:ALTS), a fintech leader in blockchain-powered digital asset management, has appointed Peter Tassiopoulos as Chief Executive Officer. Tony Issac will transition to President while remaining Chairman of the Board. Tassiopoulos brings over 30 years of leadership experience in healthcare, finance, and technology sectors.
In his new role, Tassiopoulos will guide ALT5 Sigma's strategic vision, oversee healthcare business restructuring, and drive growth in the digital asset marketplace. His experience includes completing over $1 billion in M&A, divestitures, and financing transactions. The company is exploring options to enhance stockholder value through potential strategic realignment and expansion of digital marketplace offerings.
As an inducement, Tassiopoulos was granted 400,000 restricted stock units (RSUs) that vest immediately, subject to the terms of ALT5's 2023 Equity Incentive Plan.
ALT5 Sigma (NASDAQ:ALTS), un leader fintech nella gestione di asset digitali basata su blockchain, ha nominato Peter Tassiopoulos come Amministratore Delegato. Tony Issac passerà a ricoprire il ruolo di Presidente, mantenendo la carica di Presidente del Consiglio. Tassiopoulos porta con sé oltre 30 anni di esperienza nel leadership nei settori della sanità, finanza e tecnologia.
Nel suo nuovo ruolo, Tassiopoulos guiderà la visione strategica di ALT5 Sigma, supervisionerà la ristrutturazione del business sanitario e stimolerà la crescita nel mercato degli asset digitali. La sua esperienza include il completamento di oltre 1 miliardo di dollari in operazioni di M&A, dismissioni e transazioni di finanziamento. L'azienda sta esplorando opzioni per aumentare il valore per gli azionisti attraverso un potenziale riallineamento strategico e l'espansione delle offerte nel mercato digitale.
Come incentivo, a Tassiopoulos sono stati concessi 400.000 unità azionarie vincolate (RSU) che si acquisiscono immediatamente, soggette ai termini del Piano di Incentivi Azionari 2023 di ALT5.
ALT5 Sigma (NASDAQ:ALTS), un líder fintech en la gestión de activos digitales impulsada por blockchain, ha nombrado a Peter Tassiopoulos como Director Ejecutivo. Tony Issac pasará a ser Presidente, manteniendo la presidencia de la Junta. Tassiopoulos aporta más de 30 años de experiencia en liderazgo en los sectores de salud, finanzas y tecnología.
En su nuevo rol, Tassiopoulos guiará la visión estratégica de ALT5 Sigma, supervisará la reestructuración del negocio de salud y fomentará el crecimiento en el mercado de activos digitales. Su experiencia incluye la finalización de más de 1 mil millones de dólares en fusiones y adquisiciones, desinversiones y transacciones de financiamiento. La empresa está explorando opciones para aumentar el valor para los accionistas a través de un posible realineación estratégica y la expansión de las ofertas del mercado digital.
Como incentivo, a Tassiopoulos se le otorgaron 400,000 unidades de acciones restringidas (RSUs) que se adquieren de inmediato, sujeto a los términos del Plan de Incentivo de Capital 2023 de ALT5.
ALT5 Sigma (NASDAQ:ALTS)는 블록체인 기반의 디지털 자산 관리 분야의 핀테크 리더로서 Peter Tassiopoulos를 최고 경영자(CEO)로 임명했습니다. Tony Issac은 회장직을 유지하면서 사장직으로 전환될 예정입니다. Tassiopoulos는 의료, 금융 및 기술 분야에서 30년 이상의 리더십 경험을 가지고 있습니다.
그의 새로운 역할에서 Tassiopoulos는 ALT5 Sigma의 전략적 비전을 안내하고, 의료 사업의 구조조정을 감독하며, 디지털 자산 시장에서 성장 동력을 마련하게 됩니다. 그의 경력에는 10억 달러 이상의 M&A, 매각 및 자금 조달 거래를 완료한 경험이 포함됩니다. 회사는 잠재적 전략 재편과 디지털 시장 제안 확대를 통해 주주 가치를 향상시킬 수 있는 옵션을 모색하고 있습니다.
유인 조치로 Tassiopoulos는 400,000개의 제한 주식 단위(RSU)를 부여받았으며, 이는 ALT5의 2023 주식 인센티브 계획의 조건에 따라 즉시 취득됩니다.
ALT5 Sigma (NASDAQ:ALTS), un leader fintech dans la gestion d'actifs numériques alimentée par la blockchain, a nommé Peter Tassiopoulos au poste de Directeur Général. Tony Issac passera au poste de Président tout en restant Président du Conseil. Tassiopoulos apporte plus de 30 ans d'expérience en leadership dans les secteurs de la santé, de la finance et de la technologie.
Dans son nouveau rôle, Tassiopoulos orientera la vision stratégique d'ALT5 Sigma, supervisera la restructuration du secteur de la santé et stimulera la croissance du marché des actifs numériques. Son expérience comprend la réalisation de plus d'un milliard de dollars en fusions et acquisitions, cessions et transactions de financement. L'entreprise explore des options pour augmenter la valeur pour les actionnaires grâce à un éventuel réalignement stratégique et à l'expansion des offres sur le marché numérique.
En tant qu'incitation, Tassiopoulos a reçu 400 000 unités d'actions restreintes (RSU) qui se débloquent immédiatement, sous réserve des conditions du Plan d'Incitatif Équité 2023 d'ALT5.
ALT5 Sigma (NASDAQ:ALTS), ein führendes Fintech im Bereich der blockchain-basierten digitalen Vermögensverwaltung, hat Peter Tassiopoulos zum Geschäftsführer ernannt. Tony Issac wird zum Präsidenten wechseln, bleibt jedoch Vorsitzender des Vorstands. Tassiopoulos bringt über 30 Jahre Führungserfahrung in den Bereichen Gesundheitswesen, Finanzen und Technologie mit.
In seiner neuen Rolle wird Tassiopoulos die strategische Vision von ALT5 Sigma leiten, die Umstrukturierung des Gesundheitsgeschäfts überwachen und das Wachstum im digitalen Vermögensmarkt vorantreiben. Zu seinen Erfahrungen gehören über 1 Milliarde US-Dollar in M&A-Transaktionen, Veräußigungen und Finanzierungsdeals. Das Unternehmen untersucht Optionen zur Steigerung des Aktionärswertes durch potenzielle strategische Neuausrichtung und Erweiterung der digitalen Marktangebote.
Als Anreiz wurden Tassiopoulos 400.000 eingeschränkte Aktieneinheiten (RSUs) gewährt, die sofort unter dem Bedingungen des ALT5 2023 Aktienoptionsplans erworben werden.
- Appointment of experienced CEO with 30+ years of leadership in relevant sectors
- New CEO's track record of over $1 billion in M&A, divestitures, and financing transactions
- Potential strategic realignment to enhance stockholder value
- Plans to expand product offerings in the digital marketplace
- Immediate vesting of 400,000 RSUs granted to new CEO, potentially diluting existing shareholders
LAS VEGAS, NV / ACCESSWIRE / August 26, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech leader specializing in blockchain-powered technologies for digital asset management, is pleased to announce the appointment of Peter Tassiopoulos as Chief Executive Officer. Concurrently, Tony Issac will transition to the role of President while continuing as Chairman of the Board.
Peter Tassiopoulos brings over 30 years of leadership experience across the healthcare, finance, and technology sectors. His extensive background includes various executive roles in both private and public companies, focusing on mergers and acquisitions, capital market strategies, and strategic relationships.
In his new role, Tassiopoulos will steer ALT5 Sigma's strategic vision, oversee the restructuring of its healthcare business, and drive growth initiatives as the company enhances its presence in the evolving digital asset marketplace. His proven success in navigating complex transactions and leading high-impact growth strategies positions him well to guide ALT5 Sigma through its next phase of development.
"We are excited to welcome Peter to the ALT5 Sigma team," said Tony Issac, President and Chairman of the Board. "His extensive experience will be instrumental as we continue to work to unlock stockholder value and explore new market opportunities."
Tassiopoulos has previously held various C-level positions in both public and private companies, successfully completing over
"I am honored to join ALT5 Sigma as CEO," said Tassiopoulos. "I am enthusiastic about the potential of digital assets and look forward to collaborating with our talented team to drive innovation and deliver exceptional service to our customers."
Mr. Tassiopoulos's appointment comes at a time that sees ALT5 Sigma continue to explore its options to enhance stockholder value through a possible strategic realignment, entailing a redeployment of biotech assets, while contemporaneously working toward expanding its product offerings for the digital marketplace and strengthening its global market position.
In addition, the Company today announced that, as an inducement grant, our Board of Directors and our Compensation Committee granted Mr. Tassiopoulos 400,000 restricted stock units (the "RSUs"). The RSUs will vest immediately. Although granted as inducement awards outside of ALT5's 2023 Equity Incentive Plan, the RSUs are subject to the terms of that Plan. The RSUs are intended to be inducement awards under Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules and were granted outside of ALT5's 2023 Equity Incentive Plan. The Company will be filing an S-8 in respect of these RSUs in the near term.
About ALT5 Sigma
ALT5 Sigma Corporation is a Nasdaq-listed multidisciplinary organization focused on healthcare and fintech. As of June 28, 2024, the Company is part of the Russell Microcap Index.
Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US
ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
Through its biotech activities, the Company is developing innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Media Contact Investor Relations
IR@alt5sigma.com
1-800-400-2247
Contact Information
Investor Relations
Investor Relations
ir@alt5sigma.com
1-800-400-2247
SOURCE: ALT 5 Sigma
View the original press release on accesswire.com
FAQ
Who is the new CEO of ALT5 Sigma (ALTS)?
What experience does Peter Tassiopoulos bring to ALT5 Sigma (ALTS)?
What are ALT5 Sigma's (ALTS) plans for future growth?
What compensation was granted to the new CEO of ALT5 Sigma (ALTS)?
